126 related articles for article (PubMed ID: 7954417)
1. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
5. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
[TBL] [Abstract][Full Text] [Related]
7. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
Tominaga T; Suzuki T
Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
9. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
10. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
11. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
12. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Dixon JM; Renshaw L; Bellamy C; Stuart M; Hoctin-Boes G; Miller WR
Clin Cancer Res; 2000 Jun; 6(6):2229-35. PubMed ID: 10873072
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
14. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
[TBL] [Abstract][Full Text] [Related]
15. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
17. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
18. [Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
Wada T; Nomura Y; Oohashi Y; Abe O; Koyama H; Takashima S
Gan To Kagaku Ryoho; 1994 Mar; 21(4):485-93. PubMed ID: 8129389
[TBL] [Abstract][Full Text] [Related]
19. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
20. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
Boccardo F
Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
